GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Total Current Liabilities

Kintor Pharmaceutical (HKSE:09939) Total Current Liabilities : HK$245.81 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Kintor Pharmaceutical's total current liabilities for the quarter that ended in Dec. 2023 was HK$245.81

Kintor Pharmaceutical Total Current Liabilities Historical Data

The historical data trend for Kintor Pharmaceutical's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Total Current Liabilities Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 158.66 200.73 269.06 355.26 245.81

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 401.41 355.26 299.58 245.81 -

Kintor Pharmaceutical Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Kintor Pharmaceutical's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=116.487+129.317
+Other Current Liabilities+Current Deferred Liabilities
=0.0010000000000048+0
=245.81

Kintor Pharmaceutical's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=116.487+129.317
+Other Current Liabilities+Current Deferred Liabilities
=0.0010000000000048+0
=245.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Kintor Pharmaceutical Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintor Pharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Total Current Liabilities
Comparable Companies
HKSE:03681 HKSE:06996 HKSE:02142 HKSE:01875 HKSE:02126 HKSE:02197 HKSE:02185 HKSE:06628 HKSE:02137 HKSE:06998 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KNTPF:USA
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Website
https://www.kintor.com.cn
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Executives
Tong Youzhi 2101 Beneficial owner
Kt International Investment Limited 2101 Beneficial owner
Guo Chuangxing 2201 Interest of corporation controlled by you
Kg Development Limited 2101 Beneficial owner
Nomura Holdings, Inc. 2201 Interest of corporation controlled by you
Tong Youzhi 2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si 2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si 2101 Beneficial owner

Kintor Pharmaceutical Headlines

No Headlines